Recursion Pharmaceuticals Inc. Class A (RXRX)
NASDAQ: RXRXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 4.30 +0.69%
RXRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.29B
- EPS (TTM)
- -$1.00
- Dividend yield
- None
- 52-week range
- 2.77 – 7.18
- Day range
- 4.23 – 4.60
- Volume / Avg
- 40.48M / 20.28M
- Beta
- —
- Shares outstanding
- 535.34M
- Next earnings
- Nov 4, 2026
52-week range
RXRX stock today
On Oct 7, RXRX ended the session at $4.27, shedding $0.36 (7.78%), versus the S&P 500's 0.22% decline. At this level, RXRX sits in the middle of its 52-week range of $2.77 to $7.18: 40.5% below the high, set on Oct 20, 2025 and 54.2% above the low. RXRX is up 4.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 18.4%.
Recursion Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.00), so its P/E ratio is not meaningful. Recursion Pharmaceuticals's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Recursion Pharmaceuticals
Company profileRecursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Najat Khan Ph.D.
- Headquarters
- Salt Lake City, UT
- Employees
- 600
- IPO year
- 2021
- Website
- recursion.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$7.22+69.09%
- Strong buy 2
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.24
Recursion Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs RXRX |
| CLDXCelldex Therapeutics Inc. | 30.43 | -1.85% | $2.39B | vs RXRX |
| NAMSNewAmsterdam Pharma Company N.V. | 22.13 | -0.63% | $2.59B | vs RXRX |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs RXRX |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs RXRX |
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs RXRX |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs RXRX |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs RXRX |
Indexes, lists and sector
Appears in lists
Recursion Pharmaceuticals stock FAQ
What is Recursion Pharmaceuticals's stock price today?
RXRX last traded at $4.27 as of Oct 7, 4:00 PM EDT, down 7.78% on the day. Prices are delayed at least 15 minutes.
When is Recursion Pharmaceuticals's next earnings date?
Recursion Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.24.
Who is Recursion Pharmaceuticals's CEO?
Dr. Najat Khan Ph.D. is the chief executive officer of Recursion Pharmaceuticals Inc. Class A, which has about 600 employees.
What is the RXRX 52-week high?
The 52-week high for RXRX is $7.18 and the 52-week low is $2.77. The stock is currently 40.5% below its high.